01.11.11
In a new study from Italian researchers published in Alternative Medicine Review, Meriva, a proprietary formulation of curcumin with soy phospholipids from Indena, has been shown to relieve pain and increase mobility in patients with osteoarthritis as well as reduce a series of inflammatory markers.
In this new registry study, 100 patients with X-ray confirmed osteoarthritis (OA) were divided in two groups. The first one was managed using the "best available treatment" and the second group used the best available treatment plus Meriva, at a dosage corresponding to 200 mg curcumin/day.
The results showed that the Meriva-treated group had a statistically significant reduction in all primary clinical end-points, the Western Ontario and McMaster Universities (WOMAC) score, the Karnofsky Performance Scale and the treadmill walking performance test.
These results were complemented by the evaluation of a series of inflammatory markers (interleukin [IL]-1ß, , IL-6, soluble CD40 ligand [sCD40L], soluble vascular cell adhesion molecule (sVCAM)-1, and erythrocyte sedimentation rate [ESR]) that also showed a marked reduction in the Meriva-treated group, while no significant variation was observed in the "best available treatment" group. For further information: www.indena.com
In this new registry study, 100 patients with X-ray confirmed osteoarthritis (OA) were divided in two groups. The first one was managed using the "best available treatment" and the second group used the best available treatment plus Meriva, at a dosage corresponding to 200 mg curcumin/day.
The results showed that the Meriva-treated group had a statistically significant reduction in all primary clinical end-points, the Western Ontario and McMaster Universities (WOMAC) score, the Karnofsky Performance Scale and the treadmill walking performance test.
These results were complemented by the evaluation of a series of inflammatory markers (interleukin [IL]-1ß, , IL-6, soluble CD40 ligand [sCD40L], soluble vascular cell adhesion molecule (sVCAM)-1, and erythrocyte sedimentation rate [ESR]) that also showed a marked reduction in the Meriva-treated group, while no significant variation was observed in the "best available treatment" group. For further information: www.indena.com